Locust Walk’s Post

UK Biotech IPO An IPO in the U.S. market may look very appealing to your U.K. biotech company, but what about the procedural barriers that make the process challenging? Our experts have experience with this complex process and have put together a step by step guide. Please reach out to us if you would like to hear how CFGI can support you on your IPO journey. Read our eBook to see how it works: https://bit.ly/450kZHp #CFGI #UK #IPO #Biotech #GoingPublic

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC's biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector's future... Their key points are: 👉 Major pharma players are now looking to buy earlier-stage biotechs in search of long-term value. 👉 Many biotechs are well placed for sale or IPO after focusing on efficiency and delivery. 👉 Valuations are settling while innovations are driving momentum in early-stage companies. 👉 Collaborations between big and mid-cap players are creating confidence for outside investment. See more below ⬇️ #Pharma #Biotech #Biopharma

Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC's biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector's future... Their key points are: 👉 Major pharma players are now looking to buy earlier-stage biotechs in search of long-term value. 👉 Many biotechs are well placed for sale or IPO after focusing on efficiency and delivery. 👉 Valuations are settling while innovations are driving momentum in early-stage companies. 👉 Collaborations between big and mid-cap players are creating confidence for outside investment. See more below ⬇️ #Pharma #Biotech #Biopharma

BEP 2024 First Half-Year Milestones Announcement As we begin the second half of the year, we are pleased to share our achievements from the first half of 2024. We have successfully placed 18 first (A)-round fundings, towards fourteen early-stage biotech and four medical devices, companies. Moreover, we placed 21 second (B)-round fundings for life science companies that received their initial investments from us in 2022-23. Despite the summer holidays, our efforts persist as we strive to achieve our goals. Looking ahead, we eagerly anticipate the opening of the IPO market in 2025 and 2026. #BEP2024 #Milestones #Biotech #MedicalDevices #LifeSciences #FundingSuccess #InvestmentBanking #SecondRoundFunding #IPO2025 #IPO2026 #Innovation #Growth #Investment #VentureCapital #HealthcareInnovation #FutureOfBiotech #BEPUpdates #BusinessGrowth #SummerAchievements

Preparing for an initial public offering in a complex field like life sciences can be intimidating, but with the right approach, you can get through it unscathed. There are simple yet important best practices that can help your business navigate IPO prep and earn your listing. Read our eBook for a step-by-step guide to life sciences and biotechnology IPOs: https://bit.ly/3ENmVIU #CFGI #LifeSciences #IPO #GoingPublic #PublicReadiness #Biotech

CFGI’s life sciences experts understand the nuances and requirements facing companies going public, anticipating potential hurdles from the outset.

Following the sector’s best IPO start in three years, BioPharma Dive spoke with industry insiders about what they expect to see in the months ahead. #Biotech

French biotech: disappointing post-IPO performance. Over the period between January 2012 and February 2024, the analysis of the performance of French biotechs is disastrous, with only Medincell having a share price higher than that of its IPO. There are many reasons for this, with many clinical and regulatory failures confirming the binary nature of this industry. The problem is that the likelihood of seeing the light at the end of the tunnel is low for many companies. Is the peak negative sentiment is behind or ahead of us?

Biotech’s IPO outlook for the rest of the year sours in wake of war, broader industry struggles >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech

Interesting article on Biotech IPO outlook. Section 382, transaction costs, and R&D/IRC 174 are important tax considerations when planning for an IPO.